Establishing prostate cancer patient derived xenografts: Lessons learned from older studies

Prostate

Volumn 75, Issue 6, 2015, Pages 628-636

  Russell, Pamela J ^a   Russell, Peter ^b,c   Rudduck, Christina ^d   Tse, Brian W C ^a   Williams, Elizabeth D ^a   Raghavan, Derek ^e  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

^e LEVINE CANCER INSTITUTE   (United States)

Author keywords

animal model; cancer model; prostate cancer; xenograft

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; ANDROGEN RECEPTOR; BETA ENDORPHIN; BIOLOGICAL MARKER; CORTICOTROPIN; CYTOKERATIN 7; CYTOKERATIN 8; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; PROOPIOMELANOCORTIN; PROSTATE SPECIFIC ANTIGEN; RNA DIRECTED DNA POLYMERASE; SOMATOSTATIN; TESTOSTERONE;

ACINAR CELL CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CHEMOSENSITIVITY; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIFFERENTIATED PROSTATIC ADENOCARCINOMA; DNA CONTENT; DNA SEQUENCE; ESTROGEN THERAPY; FEMALE; FLOW CYTOMETRY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LONG TERMINAL REPEAT; MALE; MOUSE; NONHUMAN; PLOIDY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; GENETICS; NEUROENDOCRINE TUMOR; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; TESTOSTERONE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84925658135     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22946     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Attard G, Richards J, de Bono JS,. New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17 (7): 1649-1657.
3. Kirby M, Hirst C, Crawford ED,. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011; 65 (11): 1180-1192.
4. Shepard DR, Raghavan D,. Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 2010; 7 (1): 13-21.
5. Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja RA, Vincent PC,. Bladder cancer xenografts: A model of tumor cell heterogeneity. Cancer Res 1986; 46 ((4 Pt 2)): 2035-2040.
6. Russell PJ, Jelbart M, Wills E, Singh S, Wass J, Wotherspoon J, Raghavan D,. Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer 1988; 41 (1): 74-82.
7. Russell PJ, Wills EJ, Philips J, Wass J, Jelbart M, Gregory P, Raghavan D,. Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: Evidence of a common histogenesis. Urol Res 1988; 16 (2): 79-84.
8. Ford SA, Russell PJ, Jelbart M, Raghavan D,. Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting. Urol Res 1989; 17 (5): 305-310.
9. Pendyala L, Velagapudi S, Toth K, Zdanowicz J, Glaves D, Slocum H, Perez R, Huben R, Creaven PJ, Raghavan D,. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997; 3 (5): 793-798.
10. Glaves D, Murray MK, Raghavan D,. Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: Analysis in a preclinical survival model. Clin Cancer Res 1996; 2 (8): 1315-1319.
11. Sharma A, Glaves D, Porter CW, Raghavan D, Bernacki RJ,. Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. Clin Cancer Res 1997; 3 (8): 1239-1244.
12. Bailey MJ, Jones AJ, Shorthouse AJ, Raghaven D, Selby P, Gibbs J, Peckham MJ,. Limitations of the human tumour xenograft system in individual patient drug sensitivity testing. Br J Cancer 1984; 50 (5): 721-724.
13. Raghavan D,. Bladder cancer: Optimal application of preclinical models to suitable translational questions. Sci Transl Med 2010; 2 (22): 22ps11.
14. van Haaften-Day C, Raghavan D, Russell P, Wills EJ, Gregory P, Tilley W, Horsfall DJ,. Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma. Prostate 1987; 11 (3): 271-279.
15. Jelbart ME, Russell PJ, Fullerton M, Russell P, Funder J, Raghavan D,. Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Mol Cell Endocrinol 1988; 55 (2-3): 167-172.
16. Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, Wills EJ, Raghavan D,. Site-specific growth of the prostate xenograft line UCRU-PR-2. Prostate 1989; 14 (2): 163-175.
17. Pittman S, Russell PJ, Jelbart ME, Wass J, Raghavan D,. Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: A xenografted cell line. Cancer Genet Cytogenet 1987; 26 (1): 165-169.
18. van Steenbrugge GJ, Groen M, Romijn JC, Schroder FH,. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J Urol 1984; 131 (4): 812-817.
19. Howe E, Howe C, Pollard I,. Plasma testosterone in the male, progesterone and estradiol-17 beta in the female, and delta 5-3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in the testis and ovary of the Snell dwarf mouse. Biol Reprod 1980; 23 (4): 887-892.
20. Sternberger LA, Hardy PH, Jr., Cuculis JJ, Meyer HG,. The unlabeled antibody enzyme method of immunohistochemistry: Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970; 18 (5): 315-333.
21. Taylor IW,. A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem 1980; 28 (9): 1021-1024.
22. Hillen H, Wessels J, Haanen C,. Bone-marrow-profileration patterns in acute myeloblastic leukaemia determined by pulse cytophotometry. Lancet 1975; 1 (7907): 609-611.
23. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA,. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31 (11): 1333-1335.
24. Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA,. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960; 20: 613-616.
25. Seabright M,. A rapid banding technique for human chromosomes. Lancet 1971; 2 (7731): 971-972.
26. ISCN An international system for human cytogenetic nomenclature (1978) ISCN (1978). Report of the Standing Commitee on Human Cytogenetic Nomenclature. Cytogenet Cell Genet 1978;21(6):309-409.
27. Russell PJ, Brown J, Grimmond S, Stapleton P, Russell P, Raghavan D, Symonds G,. Tumour-induced host stromal-cell transformation: Induction of mouse spindle-cell fibrosarcoma not mediated by gene transfer. Int J Cancer 1990; 46 (2): 299-309.
28. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG,. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59 (10): 1803-1809.
29. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ,. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20 (14): 3072-3080.
30. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM,. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30 (36): e386-e389.
31. Ghali VS, Garcia RL,. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature. Cancer 1984; 54 (6): 1043-1048.
32. Vuitch MF, Mendelsohn G,. Relationship of ectopic ACTH production to tumor differentiation: A morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer 1981; 47 (2): 296-299.
33. Gibas Z, Becher R, Kawinski E, Horoszewicz J, Sandberg AA,. A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet Cytogenet 1984; 11 (4): 399-404.
34. Grossman HB, Wedemeyer G, Ren L, Carey TE,. UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. Cancer Res 1984; 44 (9): 4111-4117.
35. Sandberg AA,. The prostatic cell: Chromosomal and DNA analyses. Prog Clin Biol Res 1981; 75A: 75-92.
36. Le Beau MM, Westbrook CA, Diaz MO, Rowley JD,. Evidence for two distinct c-src loci on human chromosomes 1 and 20. Nature 1984; 312 (5989): 70-71.
37. Wurster-Hill DH, Cannizzaro LA, Pettengill OS, Sorenson GD, Cate CC, Maurer LH,. Cytogenetics of small cell carcinoma of the lung. Cancer Genet Cytogenet 1984; 13 (4): 303-330.
38. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN,. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 2011; 71 (8): 846-856.
39. McKeithen D, Graham T, Chung LW, Odero-Marah V,. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010; 70 (9): 982-992.
40. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC,. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227 (3): 286-297.
41. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A,. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014; 42 (2): 999-1015.
42. Michiel Sedelaar, Dalrymple JP, Isaacs SS,. Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 2013; 73 (12): 1316-1325.
43. McCulloch DR, Opeskin K, Thompson EW, Williams ED,. BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis. Prostate 2005; 65 (1): 35-43.
44. Nguyen H, Corey E, Morrissey C, Nelson P, Zhang X, Roudier M, Plymate S, True L, Higano C, Montgomery R, Lange P, Vessella R,. Abstract 305: The biological and molecular characterization of clinically relevant prostate cancer xenograft lines (LuCaP series), including responses to therapy. Cancer Res 2013; 73 (8 Supplement): 305.
45. Toivanen R, Taylor RA, Pook DW, Ellem SJ, Risbridger GP,. Breaking through a roadblock in prostate cancer research: An update on human model systems. J Steroid Biochem Mol Biol 2012; 131 (3-5): 122-131.
46. Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW,. Next generation patient-derived prostate cancer xenograft models. Asian J Androl 2014; 16 (3): 407-412.
47. Zhao H, Nolley R, Chen Z, Peehl DM,. Tissue slice grafts: An in vivo model of human prostate androgen signaling. Am J Pathol 2010; 177 (1): 229-239.
48. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED,. Beresford-Smith B., Xenome-a tool for classifying reads from xenograft samples. Bioinformatics 2012; 28 (12): i172-i178.